Long-term efficacy of intravenous immunoglobulin therapy for moderate to severe childhood atopic dermatitis

Allergy, Asthma and Immunology Research

Volumn 3, Issue 2, 2011, Pages 89-95

  Jee, Sue Jung ^a   Kim, Joo Hwa ^a   Baek, Hey Sung ^a   Lee, Ha Baik ^a   Oh, Jae Won ^a  

^a Hanyang University College of Medicine   (South Korea)

Author keywords

Atopic dermatitis; Intravenous immunoglobulin

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 5; PLACEBO; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; PRESCHOOL CHILD; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TH1 CELL; TH2 CELL;

EID: 79953167198     PISSN: 20927355     EISSN: 20927363     Source Type: Journal    
DOI: 10.4168/aair.2011.3.2.89     Document Type: Article

References (28)

1. Hanifin JM, Chan SC. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. J Invest Dermatol 1995;105:84S-8S.
2. Sonenthal KR, Grammer LC, Patterson R. Do some patients with atopic dermatitis require long-term oral steroid therapy? J Allergy Clin Immunol 1993;91:971-3.
3. Sowden JM, Berth-Jones J, Ross JS, Motley RJ, Marks R, Finlay AY, Salek MS, Graham-Brown RA, Allen BR, Camp RD. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991;338:137-40.
4. Salek MS, Finlay AY, Luscombe DK, Allen BR, Berth-Jones J, Camp RD, Graham-Brown RA, Khan GK, Marks R, Motley RJ. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double-blind, placebo-controlled trial. Br J Dermatol 1993;129:422-30.
5. Grossman RM, Chevret S, Abi-Rached J, Blanchet F, Dubertret L. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996;132:623-9.
6. Kirby B, Owen CM, Blewitt RW, Yates VM. Cutaneous T-cell lymphoma developing in a patient on cyclosporin therapy. J Am Acad Dermatol 2002;47:S165-7.
7. Sewell WA, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology 2002;107:387-93.
8. Spahn JD, Leung DY, Chan MT, Szefler SJ, Gelfand EW. Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin. J Allergy Clin Immunol 1999;103:421-6.
9. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291:484-6.
10. Andersson J, Skansén-Saphir U, Sparrelid E, Andersson U. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 1996;104 Suppl 1:10-20.
11. Bayry J, Lacroix-Desmazes S, Delignat S, Mouthon L, Weill B, Kazatchkine MD, Kaveri SV. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:3497-502.
12. Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, Chevailler A, Mouthon L, Weill B, Bruneval P, Kazatchkine MD, Kaveri SV. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003;101:758-65.
13. Jolles S, Sewell C, Webster D, Ryan A, Heelan B, Waite A, Rustin M. Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts. Acta Derm Venereol 2003;83:433-7.
14. Jolles S, Hughes J, Rustin M. The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature. Br J Dermatol 2000;142:551-4.
15. Kimata H. High dose gammaglobulin treatment for atopic dermatitis. Arch Dis Child 1994;70:335-6.
16. Wakim M, Alazard M, Yajima A, Speights D, Saxon A, Stiehm ER. High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome. Ann Allergy Asthma Immunol 1998;81:153-8.
17. Paul C, Lahfa M, Bachelez H, Chevret S, Dubertret L. A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol 2002;147:518-22.
18. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl 1980;114:146-8.
19. Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol 2007;87:206-18.
20. Kowalzick L, Kleinheinz A, Neuber K, Weichenthal M, Köhler I, Ring J. Elevated serum levels of soluble adhesion molecules ICAM-1 and ELAM-1 in patients with severe atopic eczema and influence of UVA1 treatment. Dermatology 1995;190:14-8.
21. Wakita H, Sakamoto T, Tokura Y, Takigawa M. E-selectin and vascular cell adhesion molecule-1 as critical adhesion molecules for infiltration of T lymphocytes and eosinophils in atopic dermatitis. J Cutan Pathol 1994;21:33-9.
22. Halmerbauer G, Frischer T, Koller DY. Monitoring of disease activity by measurement of inflammatory markers in atopic dermatitis in childhood. Allergy 1997;52:765-9.
23. Grewe M, Bruijnzeel-Koomen CA, Schöpf E, Thepen T, Langeveld-Wildschut AG, Ruzicka T, Krutmann J. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 1998;19:359-61.
24. Chan S, Henderson WR Jr, Li SH, Hanifin JM. Prostaglandin E2 control of T cell cytokine production is functionally related to the reduced lymphocyte proliferation in atopic dermatitis. J Allergy Clin Immunol 1996;97:85-94.
25. Thepen T, Langeveld-Wildschut EG, Bihari IC, van Wichen DF, van Reijsen FC, Mudde GC, Bruijnzeel-Koomen CA. Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study. J Allergy Clin Immunol 1996;97:828-37.
26. Hamid Q, Naseer T, Minshall EM, Song YL, Boguniewicz M, Leung DY. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol 1996;98:225-31.
27. Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 2006;6:592-9.
28. Nydegger UE, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf 1999;21:171-85.